Center of Excellence for Individualization of Therapy for Breast Cancer
Annual rept. 1 Apr 2008-31 Mar 2009
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
Pagination or Media Count:
We have been waiting for the group to accumulate at least 20 serum samples from each of the patient sets we decided would benefit from a proteomic analysis. We revised this approach during the March meeting, since the collection process has been going very slowly. During the meeting, we decided to begin a somewhat different series of analyses, in which we would look at the baseline proteomic signatures for all of those patients enrolled in each arm of COE01 and -02 and attempt to correlate these signatures with the response of these patients to treatment. We further proposed to perform a set of proteomic analyses using an affinity chromatography approach in which genomic and pharmacogenomic markers identified by Dr. Changs and Dr. Leyland-Jones laboratories would become the target of our screening approaches. The goal is to see whether we can identify these specific markers in serum and tissue specimens derived from these specific trials using antibodies to these proteins that had been immobilized onto SELDI chips. In addition, we proposed to use the metal binding chip surface IMAC to evaluate these specimens for the presence of specific phosphorylated proteins including those associated with the signal transduction pathways utilized by the breast cancer cells within these tumor specimens. While we were waiting for the appropriate minimum number of specimens to be collected for analysis, Ms. Dobrolecki, the technician we had trained to be the individual running these analyses moved with her husband to a new position in Houston. We have appointed a new research assistant, Ms. Brandy Snider, to replace Ms. Dobrolecki. Brandy is learning how to use the SELDI mass spectrometer at this time, and should be able to begin these studies within a few weeks.
- Medicine and Medical Research